MUC1 and neoplasm: Targeting tumor-associated MUC1 with agents like TAB004 has shown promise in reducing colony-forming potential and triggering anoikis in pancreatic ductal adenocarcinoma (PDA) cells, suggesting its potential to curb tumor relapse, prevent metastasis, and enhance chemotherapy efficacy [248].